Richter CEO: performance is in line with annual plans

He announced that this year, after filtering out exchange rate effects, they expect an increase of about 10 percent in both revenues and adjusted EBIT (earnings before interest and taxes).

He added that they closed a favorable quarter, with pharmaceutical production accounting for 98 percent of sales. Pharmaceutical production sales increased by 11 percent to HUF 237.5 billion in the second quarter, which resulted in sales of HUF 458 billion in the first half of the year with an increase of 11 percent.

The performance of the gynecological sector accelerated significantly, expanding by 19 percent in the second quarter, and six-month sales increased by 12.9 percent to HUF 168.8 billion. Most of the growth came from Western and Eastern European markets, with all key therapeutic segments (infertility, menopause and endometriosis treatment) achieving double-digit growth in both the second quarter and the first half of the year, and even contraception registered higher sales compared to the same period last year.

Generic pharmaceuticals sector revenue grew by 7.7 percent to over HUF 130 billion, with growth slowing in the second quarter due to a high base and weaker volumes, he noted. Research and development expenses increased by 8 percent, accounting for 11 percent of sales in the first half of this year.

CFO László Kovács reported that exchange rate losses reduced net profit in the first six months of 2025: while last year, an exchange rate gain of HUF 24.2 billion was recorded, this year it was HUF 3.2 billion in the same period. Net interest income was HUF 2.5 billion, while other financial items, mainly derivative transactions, contributed HUF 6.5 billion to profit.